Precision BioSciences (NASDAQ:DTIL) Issues Earnings Results

Precision BioSciences (NASDAQ:DTIL) announced its earnings results on Wednesday. The company reported ($3.20) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($1.11), Zacks reports. Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.28 million.

Precision BioSciences Stock Performance

Shares of DTIL stock traded up $0.12 during trading hours on Friday, reaching $4.66. 23,340 shares of the company’s stock were exchanged, compared to its average volume of 172,074. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company’s 50 day moving average is $5.12 and its two-hundred day moving average is $6.59. The company has a market cap of $35.72 million, a P/E ratio of 77.43 and a beta of 1.59. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $15.97.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DTIL shares. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday.

Insider Activity at Precision BioSciences

In other news, insider J. Jefferson Smith sold 10,287 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the transaction, the insider now owns 87,440 shares in the company, valued at $418,837.60. This trade represents a 10.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total transaction of $172,033.46. Following the sale, the chief executive officer now directly owns 107,087 shares in the company, valued at approximately $500,096.29. This represents a 25.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,243 shares of company stock worth $227,424 over the last three months. 4.00% of the stock is currently owned by corporate insiders.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.